SCHEMBL4355345

SCHEMBL4355345

O=C(O)Oc1csc(-c2cccc(Cl)c2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 1/20 0.51
L3MBTL1 Q9Y468 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MAPT P10636 3/20 0.50
KMT2A Q03164 2/20 0.50
LMNA P02545 2/20 0.50
GAA P10253 2/20 0.50
KDM4E B2RXH2 2/20 0.50
ATM Q13315 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
EIF4E P06730 1/20 0.44
CYP19A1 P11511 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
PIM1 P11309 2/20 0.43
ABL1 P00519 1/20 0.43
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9555462 0.88 L3MBTL1 (0.50) TLR7L3MBTL1SMN1; SMN2MAPTKMT2A
SCHEMBL4350914 0.84 HDAC1 (0.51) TLR7L3MBTL1SMN1; SMN2MAPTKMT2A
SCHEMBL1829195 0.79 SMN1; SMN2 (0.43) SMN1; SMN2MAPTLMNAGAAKDM4E
SCHEMBL4355343 0.78 TLR7 (0.64) TLR7L3MBTL1SMN1; SMN2MAPTKMT2A
SCHEMBL11102756 0.78 CYP19A1 (0.47) L3MBTL1SMN1; SMN2MAPTLMNAGAA
SCHEMBL2928098 0.76 HPGD (0.49) SMN1; SMN2MAPTKMT2ALMNAKDM4E
SCHEMBL9555459 0.76 KDM4E (0.71) TLR7L3MBTL1SMN1; SMN2MAPTKMT2A
SCHEMBL369872 0.76 CYP19A1 (0.59) TLR7MAPTGAAKDM4EALDH1A1
SCHEMBL3057919 0.75 TLR7 (0.64) TLR7L3MBTL1SMN1; SMN2MAPTKMT2A
SCHEMBL12171802 0.74 CYP19A1 (0.67) L3MBTL1SMN1; SMN2MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2070916-A1 2-Arylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine Bayer Schering Pharma Aktiengesellschaft (DE) 2009-06-17 EP disclosed